Where ESG fits in clinical vendor oversight
- ESG impact is driven largely by outsourced trial activities such as logistics, labs, technology, and patient support
- Decision-grade ESG data should be material, comparable across suppliers, and actionable within governance routines
- The highest leverage points are supplier selection, risk-based oversight planning, QBR scorecards, and corrective action processes
- Embedding a small number of standardized ESG metrics into existing vendor governance improves durability without adding bureaucracy
Clinical development organizations are under growing pressure to demonstrate credible environmental, social, and governance (ESG) performance, particularly across value chain (Scope 3) emissions and supplier practices. Simultaneously, trial teams are managing increasing protocol complexity and relying on a larger network of specialized vendors. Recent industry discussion has highlighted these dynamics across digital trial technology, patient travel burden, and clinical trial supply chain sustainability.1,2
This article explains why ESG efforts often fail to stick when they are managed as a parallel reporting exercise and provides a practical approach for sponsors to embed ESG into existing vendor oversight mechanisms without creating a new bureaucracy. The intent is not to expand Good Clinical Practice (GCP) requirements. The intent is to integrate ESG signals into the same operating discipline that clinical teams already use to manage risk, performance, and continuous improvement.
Why ESG is moving into the clinical operations lane
Most sponsors’ clinical development footprints are shaped by outsourced work. Technology platforms, central laboratories, specialty logistics, depots, imaging providers, home nursing networks, packaging, and site support services all influence emissions, waste, and patient experience. Those impact drivers are rarely visible through corporate policies alone. They are visible through trial design choices and supplier delivery models. The discussion of emissions drivers, including travel, logistics, and trial operations, reflects this reality.2
A second reality is that the operational data needed to quantify and manage footprint is often held by vendors and their subcontractors. Studna has described the industry’s efforts to build practical tools and frameworks to assess clinical trial carbon footprint, in part because data collection has historically been inconsistent across stakeholders.3 The implication for clinical operations leaders is practical: If ESG performance is expected, it must be built into the way vendors are selected, governed, and improved.
The most common failure mode: ESG as a reporting system
In practice, many ESG programs in clinical development are designed primarily to collect documentation, score suppliers, and support corporate reporting timelines. Vendor oversight is designed to manage operational risk and delivery performance.
When ESG remains a reporting system, organizations frequently see the following:
- Questionnaires that generate noncomparable data across suppliers
- Metrics without clear boundaries, methods, or auditability
- Improvement actions that are not connected to ongoing vendor governance routines
This mismatch creates friction. Sponsors feel they are making progress because they have completed surveys. Suppliers experience repeated information requests that do not translate into clear operational priorities. Under delivery pressure, teams revert to what is governed and measured. If ESG is outside those routines, it is vulnerable to being deprioritized.
Why ESG is increasingly part of the quality equation
Treating ESG as part of vendor oversight does not require claiming that ESG and GxP are the same. The more grounded point is that ESG readiness often correlates with operational maturity. Suppliers that can produce consistent, decision-grade ESG data typically have defined process ownership, stronger data governance, clearer documentation discipline, and established escalation paths. Those same characteristics reduce surprises in delivery and improve readiness for audits beyond ESG.
In my experience across sponsor and vendor environments, the strongest oversight programs share a simple feature: They translate expectations into measurable performance, reviewed on a cadence, with clear ownership for corrective actions. ESG data that cannot meet those standards rarely change behavior. ESG data that are decision grade can become useful risk and performance signals, just as quality and delivery metrics are used today.
Shift the target from “perfect ESG data” to decision-grade ESG
Most trial organizations do not need perfect ESG data across every vendor. They need decision-grade data that are fit for vendor selection, oversight, and improvement. The Greenhouse Gas Protocol’s Scope 3 standard emphasizes understanding value chain emissions to focus efforts on the most significant reduction opportunities, using standardized approaches.4
Decision-grade ESG has 3 characteristics:
- It is material to the service being delivered. Focus on footprint and social risk drivers that actually move with the vendor’s work.
- It is comparable across suppliers. Use standardized definitions, boundaries, and assumptions so the data are interpretable.
- It is actionable within governance. Data should feed decisions: supplier selection, network design, shipment strategy, packaging choices, monitoring models, and corrective actions.
A practical way to implement this is through a tiered maturity model. Tier 1 metrics are baseline and self-reported, useful for direction-setting. Tier 2 metrics use standardized boundaries and definitions, enabling comparisons and trend management. Tier 3 applies selective verification for the most material categories, supporting stronger assurance. This tiering approach can reduce burden while improving credibility over time.
Where to embed ESG in the vendor oversight lifecycle
The most efficient way to operationalize ESG is to embed it into existing oversight moments. Four points in the vendor lifecycle typically provide the highest leverage.
1. Supplier qualification and selection
Add ESG criteria in a way that reflects materiality and maturity rather than applying uniform requirements. As Henderson noted, the lack of a single standard reference for calculating trial emissions and the need to use evolving tools and consistent methods.2 In practical terms, sponsors can segment suppliers by ESG influence and operational criticality, then tailor the ESG ask by category.
Practical steps:
